PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/00 — A2

(11) International Publication Number: **WO 00/14113**

(43) International Publication Date: 16 March 2000 (16.03.00)

(21) International Application Number: PCT/US99/20829

(22) International Filing Date: 9 September 1999 (09.09.99)

(30) Priority Data:
09/149,977 9 September 1998 (09.09.98) US

(71) Applicant *(for all designated States except US)*: MYELOS CORPORATION [US/US]; Suite M, 4940 Carroll Canyon Road, San Diego, CA 92121 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: O'BRIEN, John, S. [US/US]; 8459 Sugarman Drive, La Jolla, CA 92037 (US). PARKS, D., Elliot [US/US]; 709 Kalamath Drive, Del Mar, CA 92014 (US).

(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD OF STIMULATING PROSAPOSIN RECEPTOR ACTIVITY

(57) Abstract

A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either *in vivo* or used to transfect neural cells or neural stem cells *ex vivo* followed by reintroduction of the cells into an individual.